195 related articles for article (PubMed ID: 1666494)
1. Daptomycin disrupts membrane potential in growing Staphylococcus aureus.
Alborn WE; Allen NE; Preston DA
Antimicrob Agents Chemother; 1991 Nov; 35(11):2282-7. PubMed ID: 1666494
[TBL] [Abstract][Full Text] [Related]
2. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus.
Silverman JA; Perlmutter NG; Shapiro HM
Antimicrob Agents Chemother; 2003 Aug; 47(8):2538-44. PubMed ID: 12878516
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032.
Allen NE; Hobbs JN; Alborn WE
Antimicrob Agents Chemother; 1987 Jul; 31(7):1093-9. PubMed ID: 2821889
[TBL] [Abstract][Full Text] [Related]
4. In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains.
Bush LM; Boscia JA; Wendeler M; Pitsakis PG; Kaye D
Antimicrob Agents Chemother; 1989 Aug; 33(8):1198-200. PubMed ID: 2552901
[TBL] [Abstract][Full Text] [Related]
5. Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus.
Flandrois JP; Fardel G; Carret G
Antimicrob Agents Chemother; 1988 Apr; 32(4):454-7. PubMed ID: 2837137
[TBL] [Abstract][Full Text] [Related]
6. In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis.
Coudron PE; Johnston JL; Archer GL
J Antimicrob Chemother; 1987 Oct; 20(4):505-11. PubMed ID: 2824426
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activity of the new peptolide antibiotic LY146032 against staphylococci.
Peters G; Schumacher-Perdreau F; Pulverer G
Eur J Clin Microbiol; 1987 Dec; 6(6):685. PubMed ID: 2831047
[No Abstract] [Full Text] [Related]
8. In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis.
Laganas V; Alder J; Silverman JA
Antimicrob Agents Chemother; 2003 Aug; 47(8):2682-4. PubMed ID: 12878541
[TBL] [Abstract][Full Text] [Related]
9. Resistance studies with daptomycin.
Silverman JA; Oliver N; Andrew T; Li T
Antimicrob Agents Chemother; 2001 Jun; 45(6):1799-802. PubMed ID: 11353628
[TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of daptomycin against a worldwide collection of methicillin-resistant Staphylococcus aureus.
Brumfitt W; Hamilton-Miller JM
Drugs Exp Clin Res; 1992; 18(9):367-9. PubMed ID: 1338590
[TBL] [Abstract][Full Text] [Related]
11. Antibacterial mechanism of daptomycin antibiotic against Staphylococcus aureus based on a quantitative bacterial proteome analysis.
Ma W; Zhang D; Li G; Liu J; He G; Zhang P; Yang L; Zhu H; Xu N; Liang S
J Proteomics; 2017 Jan; 150():242-251. PubMed ID: 27693894
[TBL] [Abstract][Full Text] [Related]
12. Scanning electronmicroscopy of Staphylococcus aureus and Enterococcus faecalis exposed to daptomycin.
Wale LJ; Shelton AP; Greenwood D
J Med Microbiol; 1989 Sep; 30(1):45-9. PubMed ID: 2550648
[TBL] [Abstract][Full Text] [Related]
13. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.
Stratton CW; Liu C; Weeks LS
Antimicrob Agents Chemother; 1987 Aug; 31(8):1210-5. PubMed ID: 2820300
[TBL] [Abstract][Full Text] [Related]
14. Gain-of-Function Mutations in the Phospholipid Flippase MprF Confer Specific Daptomycin Resistance.
Ernst CM; Slavetinsky CJ; Kuhn S; Hauser JN; Nega M; Mishra NN; Gekeler C; Bayer AS; Peschel A
mBio; 2018 Dec; 9(6):. PubMed ID: 30563904
[TBL] [Abstract][Full Text] [Related]
15. Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium.
Lamp KC; Rybak MJ
Antimicrob Agents Chemother; 1993 Mar; 37(3):605-9. PubMed ID: 8384822
[TBL] [Abstract][Full Text] [Related]
16. Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype.
Begic D; von Eiff C; Tsuji BT
J Antimicrob Chemother; 2009 May; 63(5):977-81. PubMed ID: 19304733
[TBL] [Abstract][Full Text] [Related]
17. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.
Lamp KC; Rybak MJ; Bailey EM; Kaatz GW
Antimicrob Agents Chemother; 1992 Dec; 36(12):2709-14. PubMed ID: 1336344
[TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of LY146032 against Staphylococcus aureus, Listeria monocytogenes, Corynebacterium JK, and Bacillus spp., in comparison with various antibiotics.
Van der Auwera P; Grenier P; Klastersky J
J Antimicrob Chemother; 1987 Aug; 20(2):209-12. PubMed ID: 2822648
[TBL] [Abstract][Full Text] [Related]
19. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin.
Brinch KS; Tulkens PM; Van Bambeke F; Frimodt-Møller N; Høiby N; Kristensen HH
J Antimicrob Chemother; 2010 Aug; 65(8):1720-4. PubMed ID: 20534628
[TBL] [Abstract][Full Text] [Related]
20. Turbidimetric response of Staphylococcus aureus and Enterococcus faecalis to daptomycin.
Wale MC; Wale LJ; Greenwood D
Eur J Clin Microbiol Infect Dis; 1988 Dec; 7(6):809-12. PubMed ID: 2850913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
